(S) -Laudanosine

(S) -Laudanosine is an alkaloid that can be found in poppies and is the S-enantiomer of Laudanosine. Laudanosine acts on the central nervous system and cardiovascular system, inhibiting low-affinity GABA receptors with an IC50 value of 10 μM, and can cause seizures, hypotension, and bradycardia. Additionally, Laudanosine exerts analgesic effects by competitively binding to the opioid Mu-1 receptor (Ki = 2.7 μM) [1][2][3][4].

Product Specifications

CAS Number

[2688-77-9]

UNSPSC

12352005

Hazard Statement

H301, H312, H330, H410

Target

GABA Receptor; Opioid Receptor

Type

Natural Products

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/s-laudanosine.html

Purity

99.95

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CN1[C@H](C2=C(CC1)C=C(C(OC)=C2)OC)CC3=CC=C(C(OC)=C3)OC

Molecular Formula

C21H27NO4

Molecular Weight

357.44

Precautions

H301, H312, H330, H410

References & Citations

[1]Fodale V, et al. Laudanosine, an atracurium and cisatracurium metabolite[J]. European journal of anaesthesiology, 2002, 19 (7) : 466-473.|[2]Katz Y, et al. Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity. Brain Res. 1994 May 23;646 (2) :235-41.|[3]Chuliá S, et al. Mechanism of the cardiovascular activity of laudanosine: comparison with papaverine and other benzylisoquinolines. Br J Pharmacol. 1994 Dec;113 (4) :1377-85.|[4]Chapple DJ, et al. Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. Br J Anaesth. 1987 Feb;59 (2) :218-25.